![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PCDHB2 |
Gene summary for PCDHB2 |
![]() |
Gene information | Species | Human | Gene symbol | PCDHB2 | Gene ID | 56133 |
Gene name | protocadherin beta 2 | |
Gene Alias | PCDH-BETA2 | |
Cytomap | 5q31.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q4KMG6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56133 | PCDHB2 | male-WTA | Human | Thyroid | PTC | 4.82e-02 | 4.69e-02 | 0.1037 |
56133 | PCDHB2 | PTC06 | Human | Thyroid | PTC | 1.69e-04 | 1.69e-01 | 0.2057 |
56133 | PCDHB2 | PTC07 | Human | Thyroid | PTC | 1.12e-09 | 1.73e-01 | 0.2044 |
56133 | PCDHB2 | ATC09 | Human | Thyroid | ATC | 2.26e-06 | 2.24e-01 | 0.2871 |
56133 | PCDHB2 | ATC11 | Human | Thyroid | ATC | 7.49e-03 | 3.98e-01 | 0.3386 |
56133 | PCDHB2 | ATC1 | Human | Thyroid | ATC | 1.52e-06 | 2.46e-01 | 0.2878 |
56133 | PCDHB2 | ATC2 | Human | Thyroid | ATC | 9.94e-09 | 7.41e-01 | 0.34 |
56133 | PCDHB2 | ATC3 | Human | Thyroid | ATC | 6.48e-06 | 3.93e-01 | 0.338 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:00508089 | Thyroid | PTC | synapse organization | 161/5968 | 426/18723 | 5.11e-03 | 2.36e-02 | 161 |
GO:003432924 | Thyroid | ATC | cell junction assembly | 187/6293 | 420/18723 | 1.71e-06 | 2.08e-05 | 187 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCDHB2 | SNV | Missense_Mutation | novel | c.581C>A | p.Pro194Gln | p.P194Q | Q9Y5E7 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
PCDHB2 | SNV | Missense_Mutation | c.966N>T | p.Gln322His | p.Q322H | Q9Y5E7 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.852) | TCGA-44-6776-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.376N>T | p.Arg126Trp | p.R126W | Q9Y5E7 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.571) | TCGA-44-6778-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.1336G>T | p.Val446Phe | p.V446F | Q9Y5E7 | protein_coding | deleterious_low_confidence(0) | benign(0.261) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD | |
PCDHB2 | SNV | Missense_Mutation | c.871N>T | p.Arg291Cys | p.R291C | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.11) | benign(0.052) | TCGA-44-A47G-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.288N>T | p.Glu96Asp | p.E96D | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.09) | benign(0.01) | TCGA-49-AARN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.1150N>C | p.Val384Leu | p.V384L | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.06) | benign(0.007) | TCGA-49-AARQ-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | c.2033N>A | p.Ala678Glu | p.A678E | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.27) | benign(0.015) | TCGA-55-6642-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PCDHB2 | SNV | Missense_Mutation | novel | c.558N>A | p.Asp186Glu | p.D186E | Q9Y5E7 | protein_coding | tolerated_low_confidence(0.22) | benign(0.005) | TCGA-55-6985-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PCDHB2 | SNV | Missense_Mutation | novel | c.1351N>A | p.Pro451Thr | p.P451T | Q9Y5E7 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-55-8089-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |